- Liver fibrosis antiviral agents are medications designed to prevent or slow the progression of liver fibrosis caused by chronic viral infections such as hepatitis B and C. These agents work by targeting the underlying viral cause, reducing liver inflammation, and preventing further scarring of the liver tissue. Liver fibrosis occurs when excessive scar tissue builds up in the liver due to continuous liver damage, which, if untreated, can progress to cirrhosis or liver failure
- This growth is primarily fueled by the rising global prevalence of hepatitis infections, particularly in developing regions, alongside increasing public awareness and improved access to advanced healthcare services. In addition, favorable government initiatives promoting early diagnosis and treatment of liver diseases are further accelerating market expansion.
- Pharmaceutical advancements have led to the development of more effective liver fibrosis antiviral agents, including combination therapies that offer higher cure rates and fewer side effects
- North America currently dominates the market due to its well-established healthcare infrastructure
